CFDA: Draft guidance? [RSABE / ABEL]

posted by libaiyi – China, 2018-06-13 03:39 (896 d 15:20 ago) – Posting: # 18895
Views: 4,111

Thanks for you reply.

Another question,
how to write the null hypothesis and alternative hypothesis for BE based on FDA or EMA method?

Complete thread:

Activity
 Admin contact
21,210 posts in 4,426 threads, 1,481 registered users;
online 12 (0 registered, 12 guests [including 6 identified bots]).
Forum time: Wednesday 17:59 CET (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5